Novavax Inc. ($NVAX) Stock Forecast: Up 11.3% Today

What is Novavax Inc.?

Novavax (NVAX) is a biotechnology company focused on developing innovative vaccines for various infectious diseases, including COVID-19. The stock is listed on the NASDAQ.

Why is Novavax Inc. going up?

NVAX stock is up 11.3% on Aug 6, 2025 17:00

• Novavax (NVAX) reported impressive Q2 earnings and revenue results, surpassing estimates by a significant margin, which likely boosted investor confidence in the company's growth prospects.
• Despite Novavax's positive performance, the stock experienced a slight dip, possibly due to concerns stemming from another company's disappointing Q2 results, which had a negative impact on the entire vaccine sector.
• The broader market saw a more significant dip compared to Novavax, indicating that while there may have been some sector-specific challenges affecting the stock, Novavax managed to outperform the market on that particular day.
• Investors should keep an eye on how Novavax navigates through the challenges in the vaccine sector and capitalizes on its strong earnings to drive future growth and stock performance.

NVAX Price Chart

NVAX Technical Analysis

NVAX News

Novavax ( NVAX ) Q2 Earnings and Revenues Top Estimates

Novavax (NVAX) delivered earnings and revenue surprises of +985.71% and +102.74%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2672854/novavax-nvax-q2-earnings-and-revenues-top-estimates

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector - Novavax ( NASDAQ:NVAX )

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna reported disappointing Q2 results. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/trading-ideas/movers/25/08/46799525/novavax-stock-dips-as-modernas-woes-weigh-on-vaccine-sector

Novavax ( NVAX ) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the most recent trading session, Novavax (NVAX) closed at $6.85, indicating a -2.28% shift from the previous trading day.

https://www.zacks.com/stock/news/2640592/novavax-nvax-sees-a-more-significant-dip-than-broader-market-some-facts-to-know

Trending Today

Natural Gas ($GAS) Commodity Forecast: Down 5.1% Today

Sunrun Inc. ($RUN) Stock Forecast: Up 5.3% Today

Hims & Hers Health Inc. ($HIMS) Stock Forecast: Down 5.4% Today

ARM Holdings plc ($ARM) Stock Forecast: Down 2.4% Today

S&P 500 Index ($SPX) Index Forecast: Down 0.4% Today

QuantumScape Corp. ($QS) Stock Forecast: Down 5.2% Today

Best Buy Co. Inc. ($BBY) Stock Forecast: Up 5.1% Today

Unity Software ($U) Stock Forecast: Down 7.7% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 8.0% Today

Credo Technology Group ($CRDO) Stock Forecast: Down 5.8% Today

Novavax Inc. Price History

19.04.2025 - NVAX Stock was down 5.6%

• The company received limited approval from the FDA for its COVID-19 vaccine, Nuvaxovid, with restrictions on usage for specific age groups and high-risk individuals.
• Despite securing FDA approval, the stock faced a bearish trend, possibly due to concerns about the limited target population for the vaccine.
• The milestone payment of $175 million from partner Sanofi SA did not seem to have a positive impact on the stock's performance.
• The market may be reacting to the news of FDA approval with new conditions, leading to uncertainty about the vaccine's widespread adoption and revenue potential.

19.04.2025 - NVAX Stock was down 6.7%

• Novavax's stock experienced a bearish movement despite the FDA granting limited approval for its COVID-19 vaccine.
• The restricted use of the vaccine to specific age groups and high-risk individuals might have raised concerns about the company's market potential and revenue prospects.
• Investors may be disappointed by the limited scope of the FDA approval, leading to a sell-off of NVAX shares as they reassess the company's position in the competitive vaccine market.
• The market reaction suggests that investors were expecting broader approval for Novavax's vaccine, and the current restrictions could impact the company's ability to capture a larger market share and generate significant revenue.

01.07.2025 - NVAX Stock was down 5.0%

• The broader market experienced mixed trading today.
• Novavax closed at $6.85, showing a -2.28% shift from the previous trading day.
• Possibly disappointing news related to the company's vaccine development progress or financial performance.
• General market sentiment impacting biotech stocks negatively.
• Investors reacting to potential delays in regulatory approvals or clinical trial results.

25.06.2025 - NVAX Stock was down 8.5%

• Despite Novavax (NVAX) sharing promising results for their bird flu vaccine in primates, the stock experienced a bearish movement.
• The market might have reacted negatively due to profit-taking by investors after a recent uptrend in the stock price.
• Investors could be cautious about the company's ability to translate positive vaccine results into commercial success in the competitive pharmaceutical industry.
• The bearish movement could also be influenced by broader market factors or sector rotation, leading to a sell-off in biotech stocks despite positive news from Novavax.

02.06.2025 - NVAX Stock was up 5.4%

• NVAX stock experienced a bearish movement, decreasing by -2.15%.
• The positive market sentiment did not reflect on NVAX, suggesting company-specific factors influenced the stock's decline.
• Investors might be reacting to recent news or developments within NVAX, leading to the downward movement despite the overall bullish market trend.
• Traders should keep an eye on upcoming announcements or updates from NVAX to better understand the stock's performance in the near future.

21.04.2025 - NVAX Stock was down 5.5%

• Novavax's stock saw a decline despite obtaining FDA approval for its COVID-19 vaccine, Nuvaxovid, which received limited approval specifically for high-risk groups and seniors.
• The FDA's decision to restrict annual COVID-19 booster approvals to high-risk individuals and request further trials for healthy adults may have influenced investor sentiment negatively towards Novavax's stock.
• The market's response could be linked to the stricter clinical trial standards set by the FDA, potentially causing concerns about Novavax's upcoming vaccine projects and commercialization prospects.
• Despite achieving a regulatory milestone and receiving a milestone payment from partner Sanofi SA, the market's emphasis on limited approval and safety evaluations likely contributed to the bearish movement in NVAX stock.

17.05.2025 - NVAX Stock was down 5.1%

• Despite promising results indicating a robust immune response in seniors from Novavax's COVID-flu combo shot, the stock trended bearishly.
• Investor profit-taking, following a recent uptick in the stock price, may have contributed to the negative market reaction.
• Concerns about Novavax's capability to effectively launch and compete with other vaccine producers in the market might have influenced investor sentiment.
• The stock's decline could also reflect broader market trends or sector rotations affecting biotechnology companies.

28.04.2025 - NVAX Stock was down 5.1%

• The decline in NVAX stock could be attributed to heightened competition and uncertainty in the vaccine sector.
• Moderna's submission to the FDA for an enhanced COVID-19 vaccine tailored to a prevalent variant might have sparked concerns about Novavax's market position and competitiveness.
• Additionally, the retraction of Moderna's FDA submission for a COVID-flu combination vaccine could have contributed to the pessimism surrounding vaccine stocks, including NVAX.
• In general, the updates and setbacks in the vaccine field related to Moderna may have eclipsed Novavax's performance, resulting in a negative shift in NVAX stock.

06.07.2025 - NVAX Stock was up 18.4%

• Novavax saw a robust uptrend in its stock price despite prevailing market conditions.
• The decline in Novavax's stock value might be linked to the repercussions of another company's disappointing Q2 performance within the vaccine industry.
• Investors seemed optimistic about Novavax's potential to recover from the drop, which likely fueled the bullish momentum.
• The market's positive outlook on Novavax's advancements in vaccine development may have also played a role in the stock's upward movement.

06.07.2025 - NVAX Stock was up 11.3%

• Novavax (NVAX) reported impressive Q2 earnings and revenue results, surpassing estimates by a significant margin, which likely boosted investor confidence in the company's growth prospects.
• Despite Novavax's positive performance, the stock experienced a slight dip, possibly due to concerns stemming from another company's disappointing Q2 results, which had a negative impact on the entire vaccine sector.
• The broader market saw a more significant dip compared to Novavax, indicating that while there may have been some sector-specific challenges affecting the stock, Novavax managed to outperform the market on that particular day.
• Investors should keep an eye on how Novavax navigates through the challenges in the vaccine sector and capitalizes on its strong earnings to drive future growth and stock performance.

08.06.2025 - NVAX Stock was up 5.6%

• Factors contributing to the bullish movement in NVAX stock include:
• Despite a slight decline in the broader market, NVAX demonstrated resilience by closing higher, showcasing strong investor confidence.
• The potential influence of RFK Jr. in the vaccine approval process may have had a positive impact on NVAX, with the company being mentioned alongside other vaccine manufacturers such as Moderna and Pfizer.
• FDA chief Prasad's decision to restrict COVID-19 vaccine approval to specific groups could have positioned NVAX favorably, potentially increasing demand for its vaccine candidates.
• Growing macro risks like tariffs and inflation may have driven investors to seek safety in healthcare stocks like NVAX, leading to an increase in its price.

24.05.2025 - NVAX Stock was up 5.1%

• NVAX displayed a notable upward trend, ending at $6.41 with a +1.75% rise compared to the previous day.
• This positive momentum in NVAX could be linked to advancements in vaccine development or favorable updates on their clinical trials.
• Despite the market's decline, NVAX's performance reflects investor confidence in its future potential.
• Investors seem hopeful about NVAX's capacity to tackle global health issues, contributing to the stock's upward trajectory.